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IT IS GENERALLY HELD that a sequence
adenomatous polyp-cancer exists in the
human large bowel. However, only 1-20/o
of polyps give rise to malignancy, and
despite claims for dysplasia the only
reliable indicator of malignancy is in-
vasion of the muscularis mucosa. This
presents problems to histopathologists,
as polyps are often removed piecemeal
and traumatized, and manv show pseudo-
invasion.
A similar problem is the pathogenetic
relationship between intestinal meta-
plasia and stomach cancer (Morson, 1955).
Metaplasia is almost always present in
stomachs bearing cancer (Correa et al.,
1970) and widespread metaplasia precedes
cancers in high-risk patients with previous
gastric surgery (Stalsberg & Taksdal,
1971) or who suffer from pernicious
anaemia (Shearman et al., 1966). Most
intestinal metaplasia, however, does not
lead to cancer, and attempts to define a
cancer-prone group in terms of increasing
dysplasia (Morson et al., 1980) have the
disadvantage of being subjective.
Using immunohistochemical methods,
it is now possible to study specific markers
in malignant cells. These markers reflect
an abnormal phenotype and are presum-
ably acquired during the evolution of the
malignant process.
They include many which occur during
early embryonic differentiation. Placental
markers, for example, have been reported
in both germ-cell and non-germ-cell car-
cinoma, including gut adenocarcinomas
(Azer et al., 1980; Engvall & Yonemoto,
1979). We have studied one such marker,
pregnancy-specific glycoprotein (SP1), in
the cells of cancer and putative pre-
malignant conditions in human stomach
and colon.
In 18 cases of carcinoma ofthe stomach,
tissues were obtained from 9 resection
specimens and 9 endoscopies. In each
case, 2 pieces of malignant tissue and 1
each of mucosa from body, cardia and
pyloric region were examined. Seventeen
biopsy specimens of atrophic gastritis
were also available for study.
Twenty cases of carcinoma of colon,
22 tubulovillous adenomas (TVA) and
8 metaplastic polyps were also studied.
In each case 2-6 blocks were available.
Blocks were fixed in 4% phosphate-
buffered formaldehyde solution at pH 7 0
and processed into paraffin wax.
Sections were cut at 5 jim, dewaxed
and washed through graded alcohols and
then 0*2M phosphate-buffered saline (PBS,
pH 7.4). One section from each was stained
with haematoxylin and eosin.
The rabbit anti-SPI was obtained
commercially (Dako) as a single batch
and an IgG concentrate prepared using
Sephacryl S200 column chromatography.
The antibody was absorbed against
cells of the "buffy" coat of human blood
and a splenic extract, to remove non-
specific cross-reacting antibodies.
This antibody was then used, diluted
1/20, in the PAP immunoperoxidase
method of Bturns (1975) with methylSI'l IN HUAMAN GUT 'TUMOURS477
green counterstain. This gave a good posi-
tive result on syncytiotrophoblast. The
staining was abolished by prior incubation
of the antibody with neat SP1I (antigen
from Dr R. Bolhn) but not hCGA (Hoechst)
or human placental lactogen.
As pure SPI was in short supply, this
method for controlling the specificity of
the reaction was only possible in the first
sample of anti-SPI reagent. Thereafter
the anti-SP] specificity was checked by
prior incubation with a saline extract of
fresh placenta, which abolished positive
staining on control slides.
Negative controls were histologically
normal gastric and colonic mucosae.
H202-alcohol blocking of endogenous
peroxidase was checked by using Diamino-
benzidine (DAB) alone, with negative
results.
Nonspecific binding of protein and the
presence of heterophile antibodies was
assessed by using PAP reagent with and
without non-immune rabbit Igo followed
by DAB.
The results in both stomach and colon
staining of positive cells was most notice-
able on the membranes, but also seen in a
granular distribution within the cyto-
plasm. The staining intensity in the placen-
tal control sections was more intense,
falling to about the same level on 4-fold
dilution of antibody. Whilst an accurate
biochemical measure of SP1 content was
not possible, tumour cells generally
appeared to produce less SPI than syn-
cytiotrophoblasts. Furthermore, not all
tumour cells produced SP1: the proportion
varied 5% to 750G. In general it was
distributed within clusters of cells.
Occasionally some stromal fibroblasts were
faintly positive.
TABLE I.-The number ofcasespositive and
negative for SP1 in the stomach
Cancer
Iiitest iial metaplasla withI (cancer'







TABLE II.-The numober of cases positive
and negative for SP] in the colon
+ -
ColoIn cancer 1 2 8
Tubulovillous adenomas 6 16
Mletaplastic polyps 2 6
Table I shows the number of cases
positive and negative for SPI in the
stomach. Using a 2-way contingency
test, x2=9X724, well outside the 95%o
confidence limits (for 2 d.f. this gives
P = 0.0077).
Table II shows the results for the colon.
Using the same contingency test the value
for x2 = 5X568, which is just within the
950/ confidence limits (P=0 059).
Thus in the stomach, SPI shows a
weak association (50%o) with cancer and
the intestinal metaplasia in cancer cases.
For colon cancer a similar association is
not proven.
SPI has been demonstrated in the serum
of patients with a variety of germ-cell
tumours (Javadpour, 1980) and in non-
trophoblastic carcinomas (Wurz, 1979).
It has been shown infrequently in the
serum of patients with breast, lung and
colon cancer (Searle et al., 1978; Grud-
zinskas et al., 1980).
However, little attention has been
given to its presence in tumour cells,
even though immunohistochemical
methods are of the same order of sen-
sitivity as most RIA tests. The only
exception has been in studies of tropho-
blastic and other germ-cell tumours
(Horne et al., 1976; Javadpour, 1980).
In this study SPI has been shown as a
marker of stomach cancer, and of the
cells of intestinal metaplasia present in
the stomach of cancer patients. It is not
present in similar intestinal metaplasia in
non-cancer cases. The positive staining
does not correspond to areas of so-called
dyplasia (Morson et al., 1980) or the
colonic type of metaplasia described by
some authors as particularly associated
with cancer (Jas & Filipe, 1980). The meta-
plasia is small-intestinal in type, complete
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with goblet cells, absorptive cells and
Paneth cells.
The frequency of positivity is, however,
low (50%o for cancer, 23% for intestinal
metaplasia associated with cancer). In
cases where a diagnosis of cancer was in
doubt, a positive result would be of con-
siderable assistance. It would be better
than a demonstration ofCEA (Goldenberg,
1976) or changes in mucosubstances (Jass
& Filipe, 1980) which are not necessarily
indicative of neoplasia. A positive result
in a metaplastic epithelium would identify
the need for a sequential appraisal of
stomach pathology.
In the colon, SPI occurs almost as
frequently in so-called pre-malignant TVA
as in malignant conditions, and is of no
assistance in deciding whether a polypoid
neoplastic mass is malignant or not.
Invasion remains the only reliable marker.
Nor is it a totally reliable marker of neo-
plasia, as the hyperplastic metaplastic
polyp is also positive on occasions. How-
ever, the two positive cases, reported in
detail elsewhere (Skinner & Whitehead,
1981) showed some areas more typical of
tubulovillous adenomas and were large.
This is an indication that metaplastic
polyps require a more careful examination
than has hitherto been usual. Estrada &
Spjut (1980) reported adenomatous
changes in 2200 of 171 hyperplastic
polyps, another indication that the nature
of the entity should be re-evaluated.
The finding of SPI in fibroblasts is of
interest in the light of the report of SPI
in the supernatants of dividing fibro-
blasts in culture (Engvall et al., 1979).
They are not seen in normal situations,
only in tumour stroma, and it is specu-
lated that in this situation they are divid-
ing and proliferating as part of a tumour
"desmoplastic reaction".
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